Meeting report, 25-26 September 2017 Copenhagen, Denmark
This study aimed to understand the patterns of HIV drug resistance in pregnant women in Mozambique. This might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care.
3rd Edition – July 2017
www.msfaccess.org
30th World AIDS Day Report
STAR Initiative, Unitaid and World Health Organization December 2018
This report reviews the latest evidence on what works to reduce HIV-related stigma and discrimination through key programmes to reduce stigma and discrimination and increase access to justice in the six settings of focus for the Global Partnership. It includes guidance for national governments and k...ey stakeholders on how stigma and discrimination harm; how the stigmatization process operates and how we can stop it; key principles of stigma- and discrimination-reduction efforts; an overview of common intervention approaches; recommendations based on the latest evidence for reducing HIV-related stigma and discrimination in the six settings; and an overview of considerations for monitoring the success of the programmatic interventions recommended for each setting.
more
This publication marks the 25th anniversary of the Beijing Declaration and Platform for Action. It is dedicated to the women leaders and allied community mobilizers who have devoted their lives to advancing the human rights and dignity of all people affected by the HIV epidemic, and to opposing soci...al injustice, gender inequality, stigma and discrimination, and violence. Unless otherwise indicated, the HIV-related statistics cited in this publication reflect the most recent UNAIDS data available.
more
Testing men for HIV during their partner’s pregnancy can guide couples-based HIV prevention and treatment, but testing rates remain low. We investigated a combination approach, using evidence-based strategies, to increase HIV testing in male partners of HIV-positive and HIV-negative ...pregnant women.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.